Photobiomodulation (PBM) also known as low-level laser (or light) therapy
(LLLT), has been known for almost 50 years but still has not gained widespread
acceptance, largely due to uncertainty about the molecular, cellular, and
tissular mechanisms of action. However, in recent years, much knowledge has been
gained in this area, which will be summarized in this review. One of the most
important chromophores is cytochrome c oxidase (unit IV in the mitochondrial
respiratory chain), which contains both heme and copper centers and absorbs
light into the near-infra-red region. The leading hypothesis is that the photons
dissociate inhibitory nitric oxide from the enzyme, leading to an increase in
electron transport, mitochondrial membrane potential and ATP production. Another
hypothesis concerns light-sensitive ion channels that can be activated allowing
calcium to enter the cell. After the initial photon absorption events, numerous
signaling pathways are activated via reactive oxygen species, cyclic AMP, NO and
Ca2+, leading to activation of transcription factors. These transcription
factors can lead to increased expression of genes related to protein synthesis,
cell migration and proliferation, anti-inflammatory signaling, anti-apoptotic
proteins, antioxidant enzymes. Stem cells and progenitor cells appear to be
particularly susceptible to LLLT.